30 completed, 6 recruiting, 5 terminated, 4 active not recruiting. 46 Phase 3, 6 Phase 2.
By phase and status
Follow Pneumovirus Infections: new trials by email Literature Review of Pneumovirus Infections trials Research Report on Pneumovirus Infections
Trials (filtered) newest first · largest first
All 46 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children SIM0916, SIM0916 Placebo - Respiratory Syncytial Virus Infection Phase 3 Recruiting 498 2026-03-11 2026-04-02 A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection. Ziresovir (AK0529), Placebo - Respiratory Syncytial Virus Infections Phase 2 / Phase 3 Recruiting 290 2026-03-03 2026-06-22 A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease RSVPreF3 OA vaccine, Placebo - Respiratory Syncytial Virus Infections Phase 3 Active not recruiting 750 2025-10-29 2026-08-03 A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo. Vaccine, Placebo - RSV Infections, RSV Immunisation Phase 3 Recruiting 13000 2025-09-03 2026-05-18 A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose RSVpreF, Placebo - RSV Infection Phase 3 Recruiting 550 2025-04-16 2026-10-14 A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants TNM001, placebo - Respiratory Syncytial Virus Infections Phase 3 Completed 315 2024-11-28 2026-03-05 A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) RSVPreF3 OA investigational vaccine, Placebo - Respiratory Syncytial Virus Infections Phase 3 Completed 751 2024-10-01 2026-06-23 RSV Vaccine in Transplant Recipients Adjuvant, non-live RSV vaccine - Vaccine Response Impaired, Respiratory Syncytial Virus Infections Phase 3 Active not recruiting 100 2024-10-01 2026-10-27 A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older RSVPreF3 OA investigational vaccine, Placebo (Saline solution) - Respiratory Syncytial Virus Infections Phase 3 Completed 2620 2024-08-05 2026-05-19 An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study RSVPreF3 OA vaccine - Respiratory Syncytial Virus Infections Phase 3 Active not recruiting 10212 2024-08-01 2026-10-01 A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults. RSVpreF MDV, RSVpreF SDV - Respiratory Syncytial Virus (RSV) Phase 3 Completed 453 2024-06-24 2025-09-25 A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above RSVPreF3 OA investigational vaccine - Respiratory Syncytial Virus Infections Phase 3 Completed 1459 2024-04-29 2025-09-25 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine - Respiratory Syncytial Virus Infections Phase 3 Completed 841 2024-04-29 2025-12-26 Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections Human interferon α1b Inhalation Solution, Inhalation Solution Placebo - Respiratory Syncytial Virus Infections Phase 3 Recruiting 322 2024-03-27 2026-07-01 A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection Sisunatovir, Placebo - Respiratory Syncytial Virus Infection Phase 2 / Phase 3 Terminated 16 2023-12-08 2025-11-10 A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants TNM001, placebo - Respiratory Syncytial Virus Infections Phase 2 / Phase 3 Completed 2282 2023-09-11 2026-03-05 A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults RSVPreF3 OA investigational vaccine, HZ/su vaccine - Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections Phase 3 Completed 530 2023-07-28 2025-04-01 A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab Nirsevimab - Respiratory Syncytial Virus Infections Phase 3 Completed 33 2023-07-27 2026-04-16 Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults RSVPreF3 OA investigational vaccine, PCV20 - Respiratory Syncytial Virus Infections Phase 3 Completed 1113 2023-05-26 2025-05-18 A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control RSVPreF3 vaccine, Control - Respiratory Syncytial Virus Infections Phase 3 Completed 3855 2023-02-07 2026-03-17
Showing 20 of 46. Sign in to see all of them.
Narrower conditions Respiratory Syncytial Virus Infections (46) · Infections (2) · Bronchopulmonary Dysplasia (1) · Heart Defects, Congenital (1) · Heart Diseases (1) · Obstetric Labor, Premature (1) · Premature Birth (1) · Tetanus (1)
Broader conditions Mononegavirales Infections (46) · Paramyxoviridae Infections (46) · RNA Virus Infections (46) · Virus Diseases (46) · Infections (44) · Cardiovascular Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Obstetric Labor Complications (2) · Pregnancy Complications (2) · Urogenital Diseases (2) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Cardiovascular Abnormalities (1) · Clostridium Infections (1)
Interventions Palivizumab (5) · Adjuvants, Pharmaceutic (2) · MK-1654 (2) · ziresovir (2) · Air (1) · Boostrix (1) · CVnCoV COVID-19 vaccine (1) · Control Groups (1) · Influenza Vaccines (1) · Ribavirin (1) · Saline Solution (1) · Vaccines (1) · arexvy (1) · heliox (1) · motavizumab (1)
Sponsors GlaxoSmithKline (21) · AstraZeneca (3) · Pfizer (3) · Merck Sharp & Dohme LLC (2) · Shanghai Ark Biopharmaceutical Co., Ltd. (2) · Zhuhai Trinomab Pharmaceutical Co., Ltd. (2) · AbbVie (prior sponsor, Abbott) (1) · Abbott (1) · Bavarian Nordic (1) · Kexing Biopharm Co., Ltd. (1) · MedImmune LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novavax (1) · Regeneron Pharmaceuticals (1) · Simcere Pharmaceutical Co., Ltd (1)
Countries United States (28) · Canada (16) · Spain (16) · South Africa (15) · Finland (14) · Japan (12) · United Kingdom (12) · Germany (11) · New Zealand (11) · Australia (10) · Belgium (10) · China (10) · Italy (10) · South Korea (9) · France (8)
Top investigators Bernard Hoet, MD (1) · Enmei Liu (1) · Enmei Liu, MD (1) · Hanmin Liu (1) · Hanmin Liu, MD (1) · Konstantin M Gudkov, MD (1) · M Pamela Griffin, MD (1) · Michele Kong, MD (1) · Shabir Madhi (1) · Shigeki Hashimoto, PhD (1)
Results publications PMID 34774184 , PMID 38921800 , PMID 20008423 , PMID 22943074 , PMID 32726529 , PMID 32897368 , PMID 35235726 , PMID 35235733 , PMID 36791160 , PMID 37018470 , PMID 37468530 , PMID 37698366 , PMID 38219024 , PMID 38314063 , PMID 38426479 , PMID 38503664 , PMID 38746060 , PMID 38902186 , PMID 38970327 , PMID 39099093 , PMID 39321361 , PMID 39461302 , PMID 39656748 , PMID 39879629 , PMID 40245915 , PMID 40246359 , PMID 40602662 , PMID 40673795 , PMID 40958705 , PMID 40961423 , PMID 40961446 , PMID 41194599 , PMID 41637686 , PMID 41660362 , PMID 41757519 , PMID 41766205 , PMID 41994955 , PMID 42054374 , PMID 42475081 , PMID 42847629
NIH funding 2023 (5) , 2019 (2) , 2025 (1) , R01HD105678 (1)